Chiral selenium-containing compounds have found growing application in asymmetric catalysis over the past few years. The large majority of these ligands are derived from readily available chiral amino alcohols in a few high-yielding synthetic steps. The advantages of using these compounds are described, particularly those regarding ready accessibility, modular nature, formation of strong bonds with soft metals and more rarely with hard ones. By using an appropriate electrophilic or nucleophilic organoselenium fragment, novel chiral organoselenium catalysts or ligands were designed from chiral aziridines, oxazolines, ferrocenes, etc. High regioselectivity and enantioselectivity were achieved through the four following techniques: the enantioselective copper-catalyzed conjugate addition of organometallic reagents to enones, the diorganozinc addition to aldehydes, palladium-catalyzed enantioselective allylic alkylation and asymmetric hydrosilylation or transfer hydrogenations of ketones.
1 May 2013 in Current Topics in Medicinal Chemistry
Pharmacophore approaches have evolved to be one of the most successful tools in drug discovery, especially since the past two decades. 3D pharmacophore methods are now commonly used as part of more complex workflows in drug discovery campaigns, and have been successfully and extensively applied in virtual screening (VS) approaches. This review provides a perspective of how to assess the performance of 3D pharmacophore models to be used in VS. Since 3D VS protocols are in general assessed by their ability to discriminate between active and inactive compounds, we summarize the impact of the composition and preparation of modeling and external sets on the outcome of evaluations. Moreover, we highlight the significance of both classic enrichment parameters and advanced descriptors for the performance of 3D pharmacophore-based virtual screening methods.